ArticleExperimental hematology & oncology2024

Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies.

Yingling Zu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.